denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Sponsor: educational grants from Agios Pharmaceuticals Inc., Jazz Pharmaceuticals and Pfizer, Inc. Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC
Program: Satellite Symposia
Hematology Disease Topics & Pathways:
Leukemia, AML, Biological, therapy sequence, apoptosis, apheresis, Adult, Diseases, Bleeding and Clotting, Non-Biological, Therapies, CAR-Ts, Combinations, Elderly, Biological Processes, Technology and Procedures, immunotherapy, epigenetics, cytogenetics, Lymphoid Malignancies, Study Population, Myeloid Malignancies, genomics, genetic profiling, TKI, molecular testing, NGS, molecular interactions
Hematology Disease Topics & Pathways:
Leukemia, AML, Biological, therapy sequence, apoptosis, apheresis, Adult, Diseases, Bleeding and Clotting, Non-Biological, Therapies, CAR-Ts, Combinations, Elderly, Biological Processes, Technology and Procedures, immunotherapy, epigenetics, cytogenetics, Lymphoid Malignancies, Study Population, Myeloid Malignancies, genomics, genetic profiling, TKI, molecular testing, NGS, molecular interactions
Friday, December 4, 2020: 7:00 AM-10:00 AM
Chair:
Farhad Ravandi, MBBS, University of Texas- MD Anderson Cancer Center, M.D. Anderson Cancer Center
Disclosures:
Ravandi: BMS: Consultancy, Honoraria, Research Funding; Astellas: Consultancy, Honoraria, Research Funding; Amgen: Consultancy, Honoraria, Research Funding; AstraZeneca: Consultancy, Honoraria; Macrogenics: Research Funding; Xencor: Consultancy, Honoraria, Research Funding; Celgene: Consultancy, Honoraria; Orsenix: Consultancy, Honoraria, Research Funding; Abbvie: Consultancy, Honoraria, Research Funding; Jazz Pharmaceuticals: Consultancy, Honoraria, Research Funding.
Speakers:
Amir T. Fathi, Massachusetts General Hospital, Massachusetts General Hospital Cancer Center
and
Alice S. Mims, MD, The Ohio State University Comprehensive Cancer Center
Disclosures:
Fathi: Takeda: Consultancy, Research Funding; Boston Biomedical: Consultancy; PTC Therapeutics: Consultancy; Amphivena: Consultancy; Astellas: Consultancy; Daiichi Sankyo: Consultancy; Novartis: Consultancy; Celgene / BMS: Consultancy, Research Funding; Kite: Consultancy; Trovagene: Consultancy; Forty Seven: Consultancy; NewLink Genetics: Consultancy; Pfizer: Consultancy; Abbvie: Consultancy; Seattle Genetics: Consultancy, Research Funding; Agios: Consultancy, Research Funding; Amgen: Consultancy; Trillium: Consultancy; Kura Oncology: Consultancy; Blueprint: Consultancy; Genentech: Consultancy. Mims: Jazz Pharmaceuticals: Other: Data Safety Monitoring Board; Abbvie: Membership on an entity's Board of Directors or advisory committees; Kura Oncology: Membership on an entity's Board of Directors or advisory committees; Leukemia and Lymphoma Society: Other: Senior Medical Director for Beat AML Study; Syndax Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; Novartis: Speakers Bureau; Agios: Consultancy.
This CME/CNE/CPE-certified webinar, developed by NCCN, will feature review of the latest clinical data, NCCN Guidelines updates, and management of different patient case studies. Renowned AML experts will provide their perspectives on recent changes in AML treatment and the rationale for the development of new and novel targeted treatment options that are individualizing the care of patients with AML. Engagement with the presenting faculty will be accomplished through technology that allows those attending to not only answer case and polling questions, but also directly submit questions and comments to the panel. In addition, the faculty will highlight available online resources along with the latest updates to the NCCN Guidelines to help provide practical insights to aid integration of new insights into practice after returning to the clinic after ASH.
See more of: Satellite Symposia